Helio Genomics, shared on LinkedIn:
“At the San Antonio Liver Cancer Symposium today, Helio Genomics is presenting four real world case studies on HelioLiver in hepatocellular carcinoma surveillance.
The question behind the posters is a practical one:
can a molecular signal help when ultrasound is negative, imaging is indeterminate, or a tumor is not yet visible?
Shivani Mahajan, PhD, Head of Computational Science at Helio, presents the work on Friday, October 9. The studies cover:
- Cases in which an abnormal HelioLiver result prompted further imaging after ultrasound had not identified a lesion
- Cases where imaging was indeterminate or definitive imaging was limited, including biopsy-confirmed HCC after an abnormal result
- Molecular signals that preceded imaging-visible disease by about six months, and definitive radiographic diagnosis by as much as nine months
- A simulation of whether HelioLiver-based surveillance could increase detection of tumors while they remain within early-stage treatment criteria, compared with ultrasound
HCC biology begins before a tumor is large enough to see clearly on a scan. Earlier molecular information may give clinicians precious lead time to act while curative treatment is still possible.
If you are at SALCS, stop by the posters on Friday and talk with Shivani.
The hardest cases in HCC surveillance are exactly where a better signal matters.”
Read the full announcement:
You may also read:
Nivolumab With deb-TACE in Liver-Limited Hepatocellular Carcinoma
